Investment Rating - The report initiates coverage with an OUTPERFORM rating, indicating a positive outlook for the company [2]. Core Insights - Auntea Jenny (Shanghai) Industrial is recognized as a leading fresh beverage company in China, having surpassed 10,000 stores by the end of 2025, making it the third brand in the industry to achieve this milestone [3][7]. - The report emphasizes that the fresh beverage industry is increasingly dominated by leading brands, with strong channel advantages allowing them to rapidly expand and innovate [3]. - The company aims to become a global leader in multi-brand fresh beverage groups, leveraging a light-asset model for rapid expansion [7]. Financial Projections - Revenue projections for the company are as follows: Rmb 3,285 million for Dec-24, Rmb 4,215 million for Dec-25, Rmb 4,918 million for Dec-26, and Rmb 5,632 million for Dec-27, reflecting growth rates of -2%, 28%, 17%, and 15% respectively [2]. - Net profit is expected to grow from Rmb 418 million in Dec-24 to Rmb 707 million in Dec-27, with growth rates of 0%, 28%, 16%, and 14% [2]. - The diluted EPS is projected to increase from Rmb 4.09 in Dec-24 to Rmb 6.72 in Dec-27 [2]. Business Model and Strategy - The company operates under a dual-brand strategy, with Auntea Jenny as the main brand and Tea Waterfall as a supporting brand, focusing on both domestic and international markets [4][16]. - The report highlights the company's successful expansion in northern China, attributed to its management philosophy of mutual benefit and resource sharing, as well as a focus on health-oriented products targeting specific consumer demographics [4][20]. - The company has established a low-barrier franchise model, allowing for rapid store expansion and a diverse franchisee base, which is crucial for sustainable growth [37]. Market Position and Competitive Landscape - Auntea Jenny has shown a strong performance in the fresh beverage market, with a compound annual growth rate (CAGR) of 57% in store numbers from 2020 to 2023, outpacing competitors [8][20]. - The report notes that the company has a significant presence in the northern market, with over half of its stores located in this region, which is a strategic advantage compared to other brands [18][20]. - The competitive landscape is characterized by increasing market concentration, with leading brands expected to gain more market share while regional brands coexist [3][4]. Future Growth Potential - The company plans to open 2,000 to 3,000 new stores in 2026, maintaining a steady expansion pace while focusing on improving growth quality [53]. - The report anticipates that the Tea Waterfall brand will accelerate its expansion, targeting lower-tier cities and leveraging the established supply chain of the main brand [52]. - The overseas expansion strategy is focused on developed markets, with successful store openings in Malaysia, the USA, and South Korea, indicating significant growth potential [52].

Investment Rating - The investment rating for OSL Group is "Buy" (maintained) [1][7] Core Insights - The strategic acquisition of Banxa Holdings Inc. enhances OSL Group's compliance capabilities and global payment infrastructure, positioning the company for significant growth in the B2B sector [4][6] - OSL Group's revenue is projected to grow significantly, with estimates of HKD 514 million in 2025, HKD 873 million in 2026, and HKD 1.172 billion in 2027, reflecting growth rates of 37.12%, 69.91%, and 34.29% respectively [5][6] - The acquisition is expected to improve OSL's payment business revenue substantially, with Banxa's revenue for the first half of 2025 estimated at HKD 53.93 million [6] Financial Projections - Revenue projections for OSL Group are as follows: HKD 375 million for 2024, HKD 514 million for 2025, HKD 873 million for 2026, and HKD 1.172 billion for 2027 [5][7] - The forecasted net profit for OSL Group shows a loss of HKD 75.74 million in 2025, a slight loss of HKD 2.56 million in 2026, and a profit of HKD 194 million in 2027 [5][6] - The Price-to-Sales (P/S) ratio is expected to decrease from 29.90 in 2024 to 9.56 in 2027, indicating improved valuation as revenue grows [5][7]

Investment Rating - The report maintains a "Buy" rating for the company [3][5]. Core Insights - The company is expected to see new developments in the upcoming Olympic cycle, with the launch of new store formats and product lines aimed at enhancing brand engagement and meeting diverse consumer needs [2][9]. - The earnings per share (EPS) forecasts for 2025, 2026, and 2027 have been slightly adjusted to 0.95, 1.07, and 1.22 RMB respectively, with a target price set at 25.41 HKD based on a 24x valuation for 2025 [3][10]. - The company has shown resilience in a challenging consumer environment, with expectations for slight revenue growth driven by specific product categories and improved operational efficiency [9]. Financial Summary - Revenue projections for the company are as follows: - 2023: 27,598 million RMB - 2024: 28,676 million RMB (growth of 3.9%) - 2025: 29,101 million RMB (growth of 1.5%) - 2026: 30,640 million RMB (growth of 5.3%) - 2027: 32,747 million RMB (growth of 6.9%) [4]. - Operating profit and net profit forecasts indicate a decline in 2025, with operating profit expected to be 3,331 million RMB and net profit at 2,465 million RMB, before recovering in subsequent years [4]. - The company’s gross margin is projected to remain stable, with estimates of 48.8% in 2025 and gradually increasing to 49.2% by 2027 [4]. - The price-to-earnings (P/E) ratio is forecasted to be 18.6 in 2025, decreasing to 14.6 by 2027, indicating a potential improvement in valuation over time [4].

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Insights - The company is positioned as a leading player in the high-end beauty and health management sector, with a well-established "Double Beauty + Double Health" ecosystem that drives growth through both organic and external expansion [8][13]. - The company has demonstrated strong revenue growth, with total revenue projected to increase from 21.45 billion in 2023 to 45.78 billion by 2027, reflecting a compound annual growth rate (CAGR) of 11.3% from 2020 to 2024 [25]. - The net profit attributable to shareholders is expected to rise from 2.16 billion in 2023 to 5.18 billion by 2027, with significant year-on-year growth rates [1][25]. Summary by Relevant Sections Company Overview - The company, established in 1993, has evolved from a lifestyle beauty business to a comprehensive beauty and health management service provider, encompassing traditional beauty, medical beauty, and sub-health assessment services [8][13]. - It has developed four major brands: Meili Tianyuan, Beili Shi, Xiuker, and Yanyuan, and has strengthened its market position through acquisitions of Nai Rui Er and Si Yan Li [13][20]. Financial Analysis - The company's revenue has shown resilience, increasing from 15.03 billion in 2020 to 25.72 billion in 2024, with a notable 28.2% growth in the first half of 2025 [25][28]. - The gross profit margin has improved from 46.57% in 2020 to 49.33% in the first half of 2025, indicating effective cost control and a higher proportion of high-margin services [28][30]. Industry Insights - The beauty and health management market is expected to grow significantly, with the traditional beauty market projected to reach 640.2 billion by 2030, and the light medical beauty market expected to expand to 415.7 billion [40][44]. - The sub-health medical service market is identified as a high-potential area, with a projected market size of 290 billion by 2030, driven by increasing awareness and demand for preventive health services [48][51]. Competitive Advantages - The company's business model leverages strong synergies between its various service lines, enhancing customer conversion rates and operational efficiency [8][13]. - The management team possesses extensive experience in the beauty and health industry, which supports the company's strategic initiatives and operational execution [22][24].

Investment Rating - The report does not explicitly provide an investment rating for WuXi AppTec [2][3]. Core Insights - The report highlights three major catalysts that may drive WuXi AppTec's stock performance in Q1 2026: 1) Updates from the industry summit scheduled for January 12-15, which is expected to support the CRO industry's outlook; 2) The release of the 1260H list in January-February 2026, which should alleviate the impact of pending policy decisions; 3) The company's full-year guidance for 2026, to be announced in March 2026 [5]. - The report indicates that in 2026, the focus for the Chinese healthcare sector will shift towards earnings realization rather than valuation multiple expansion, with WuXi AppTec expected to lead in visibility of earnings growth [7]. - The report anticipates a recovery in outsourcing demand in 2026 due to the resolution of policy and tariff uncertainties, which had previously delayed biotech financing and new R&D initiatives in 2025 [6]. Summary by Sections Company Overview - WuXi AppTec is a global enterprise with operations across Asia, Europe, and North America, providing a comprehensive range of R&D and manufacturing services to advance the pharmaceutical and healthcare industries [10]. - The company covers the entire drug development cycle through five core business segments: small molecule R&D and manufacturing, biologics R&D and manufacturing, cell and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics [10]. Revenue Breakdown - Revenue by product category: Chemical business (72.3%), Testing business (16.2%), Biological business (6.3%), High-end therapeutic CTDMO (3.2%) [11]. - Revenue by region: Middle East and Africa (8.7%), Asia (36.5%), Europe (27.3%), Americas (27.5%) [11]. Stock Information - Stock price as of January 5, 2026: 104.2 HKD - Market capitalization: 40.33 billion USD - Consensus target price (Refinitiv): 130.76 HKD [13].

Investment Rating - The report maintains an "Outperform" rating for Mao Geping Cosmetics, with a target price of HKD 108.20, indicating a potential upside of 23.1% from the current price of HKD 87.95 [2][14]. Core Insights - The cosmetics industry has seen intensified competition since 2025, a trend expected to continue into 2026. Mao Geping is anticipated to sustain strong growth in the second half of 2025, driven by robust offline same-store sales and strong online growth, despite some weakening in household consumption [3][11]. - The company has signed a strategic partnership with L Catterton, aimed at global market expansion and establishing a premium beauty investment fund, which could enhance its brand penetration in overseas markets [4][12]. - Shareholders plan to reduce their holdings by up to 3.51% of the total share capital, which may temporarily affect market sentiment, but the company emphasizes that this will not change control and the long-term fundamentals remain strong [5][13]. Financial Performance Summary - Revenue projections for Mao Geping are RMB 5.101 billion for 2025, RMB 6.489 billion for 2026, and RMB 8.115 billion for 2027, reflecting year-on-year growth rates of 31.3%, 27.2%, and 25.0% respectively [3][11]. - Net profit attributable to the parent company is expected to be RMB 1.201 billion in 2025, RMB 1.494 billion in 2026, and RMB 1.848 billion in 2027, with growth rates of 36.4%, 24.4%, and 23.7% respectively [3][11]. - The company maintains a high gross profit margin of around 84% and a return on equity (ROE) of approximately 34.9% in 2024, projected to decrease slightly in the following years [9][10].

证券研究报告 | 公司深度报告 2026 年 01 月 08 日 先瑞达医疗-B（06669.HK） 波科赋能海外可期，新产品带来增长 消费品/生物医药 先瑞达是国内领先的专注于提供泛血管介入综合解决方案的创新医疗器械平台 型企业，率先于国内推出首款膝上及膝下 DCB 产品，在外周介入领域处于领先 地位；2025 年 12 月公司与控股股东波士顿科学签署新的三年期合作协议，在 产品全球商业化、制造服务和研发等领域开展一系列合作。 ❑ 与波科签署新三年期合作协议，海外放量确定性强。2023 年 2 月全球微创介 入医疗器械领先企业波士顿科学成为先瑞达控股股东，持股 65%，并于 2023 年 6 月签署首个合作谅解备忘录；2025 年 12 月，公司与波科签署新的三年 合作协议（2026-2028）：1）全球商业化：共享波科覆盖全球的渠道资源， 预计 2026-2028 年向波科销售产品交易金额上限为 3000/6200/7800 万美元； 2）产品制造：基于先瑞达智造能力提供产品 OEM 服务，预计 2026-2028 年 向波科提供制造服务交易金额上限为 100/100/300 万美元；3）产品研发：互 相 ...

Investment Rating - The report assigns a "Buy" rating to the company, indicating a potential upside of 15% to 35% [5]. Core Insights - The company has received approval for its innovative drug, Ruira Fup α, which is a dual-function fusion protein targeting PD-L1 and TGF-βRII, marking it as the first of its kind to be approved in the market [5][8]. - The company has a robust pipeline with over 300 new drugs under development, and it is expected to launch 7 new drugs by 2025, with Ruira Fup α being approved at the start of 2026 [8]. - The company is actively pursuing business development (BD) transactions, with expected revenues from these deals exceeding USD 16 billion, which will significantly enhance profitability [8]. - Projected net profits for the company are estimated at RMB 10.1 billion, RMB 9.1 billion, and RMB 10.4 billion for the years 2025, 2026, and 2027 respectively, with year-on-year growth rates of 59.3%, -9.9%, and 14.5% [10]. Financial Summary - The company’s revenue is projected to grow from RMB 22.82 billion in 2023 to RMB 45.40 billion by 2027, reflecting a strong growth trajectory [12]. - The earnings per share (EPS) are expected to be RMB 1.52, RMB 1.37, and RMB 1.57 for the years 2025, 2026, and 2027 respectively, with a notable increase in 2025 [10]. - The company’s net profit margin is projected to be 18.5% in 2025, decreasing to 16.5% in 2026, and recovering to 17.5% in 2027 [10].

Investment Rating - The report does not provide a specific investment rating for the company [1]. Core Insights - MiniMax is positioned as a benchmark for AI expansion in China, focusing on multi-modal development to build competitive large models for the global market [7]. - The company has adopted a dual-driven business model (ToC and ToB), with consumer products generating significant cash flow and enterprise services providing high margins [7]. - MiniMax's revenue is projected to grow significantly, with estimates of $80.88 million in 2025 and $398.66 million in 2027, reflecting a compound annual growth rate of over 130% [7]. - The company has a strong global execution capability, with products covering over 2.12 billion personal users and more than 100,000 enterprise clients across 200 countries [7]. Summary by Sections Company Overview - MiniMax was established in December 2021, focusing on general AI technology development and aiming for global market presence [12]. - The company has raised over $1.5 billion in funding, with notable investors including Alibaba and Xiaomi, which supports its high R&D intensity [12][13]. - As of September 2025, MiniMax has a workforce of 385 employees, predominantly young and tech-focused, enhancing its execution efficiency [12]. Business Model - The company operates a dual-driven model, with consumer business leading in scale and cash flow, while developer enterprise business supports high margins [30]. - Consumer products include Talkie and Hailuo AI, which have shown strong performance in overseas markets, particularly in North America [31][34]. - Developer enterprise business generates revenue through API calls and model licensing, with a significant increase in paid clients from 400 in 2024 to approximately 2,500 in 2025 [39]. Technology Route and Competitive Advantages - MiniMax's core technology strategy is based on a multi-modal architecture, focusing on language, vision, and speech models [43]. - The company emphasizes a system engineering approach, ensuring high efficiency in model training and deployment [44][46]. - MiniMax's ability to rapidly iterate and improve its models positions it favorably against competitors, as it can unlock new application scenarios with each model upgrade [47][48].

Investment Rating - The report assigns an "Outperform" rating to the company [2]. Core Insights - The company's high efficiency across the supply chain, channels, and marketing is the core reason for establishing itself as a leading brand, with expectations for continued market share growth. The reuse of brand, channel, and marketing advantages to expand product categories is anticipated to further unlock growth potential, with new products expected to exceed expectations [1][4]. Financial Summary - The company’s projected earnings per share (EPS) for 2025-2027 are estimated at 0.55, 0.68, and 0.82 RMB, respectively. A target price of 18.48 HKD is set for 2026, based on a 25x price-to-earnings (PE) ratio [2][9]. - Revenue projections are as follows: - 2023: 4,869.53 million RMB - 2024: 5,745.32 million RMB (up 7.4%) - 2025: 6,929.05 million RMB (up 18.0%) - 2026: 8,188.01 million RMB (up 20.6%) - 2027: 9,453.91 million RMB (up 18.2%) [3]. Business Structure and Market Position - The rice industry lacks a total volume logic, but there is potential for growth in the mid-to-high-end rice segment due to structural upgrades. The overall competition is fragmented, with a slow increase in industry concentration. Brands positioned in the mid-to-high-end segment benefit from brand barriers and profit margins that allow for better resource allocation [2][28]. - The company has established a strong market position, with a 4% share in the pre-packaged premium rice market, leading the segment against competitors [39][42]. Product Expansion and Growth Potential - The company has a clear path for product innovation, with successful launches in new categories like corn, which is expected to drive future growth. The introduction of new products such as corn juice packs is anticipated to contribute to revenue growth [4][10]. - The company is also focusing on expanding its product categories, with plans to introduce southern rice and other new products to tap into larger growth opportunities [4][10]. Competitive Advantages - The company has built a high-efficiency supply chain in key geographical areas, ensuring quality and price advantages for raw materials. Its direct-to-consumer (D2C) sales model and order-based production enhance product freshness, contributing to a significantly higher repurchase rate compared to industry averages [4][62]. - The company’s marketing strategies and brand positioning have resulted in a strong customer base, with a high repurchase rate of 39% for its rice products, significantly above the industry average of 26% [58][62].